Cistus

What is Cistus?

Cistus got its European Union herbal monograph on 19 March 2025, for one use only: relief of cough associated with cold. The document is EMA/HMPC/150763/2015, it covers a decoction of the dried herb, and it was granted on traditional use, meaning long-standing use rather than clinical evidence. That single line of regulatory text is the whole of what the European Medicines Agency has been willing to say about this plant.

Botanically the plant is Cistus creticus L., a low pink-flowered shrub in the Cistaceae with resin-sticky leaves, native to the eastern Mediterranean and abundant on Crete, Cyprus, Greece and western Turkey, with four subspecies recognized in the EMA assessment: subsp. creticus, subsp. eriocephalus, subsp. corsicus and, recently, subsp. trabutii. Products sold in the United States generally call it Cistus incanus, which is where the trouble starts. Linnaeus published Cistus incanus in 1753, then Cistus creticus in 1762 and Cistus villosus in 1764, and by the early twentieth century the original C. incanus had been reinterpreted as a hybrid of Cistus albidus L. and Cistus crispus L. Guzman and Vargas resolved the genus phylogenetically in 2005 using ITS, trnL-trnF and matK sequence data (Molecular Phylogenetics and Evolution 37:644-660). The EMA assessment report treats Cistus incanus and Cistus x incanus as synonyms of Cistus creticus and moves on. Sellers do not.

The plant also produces labdanum, a fragrant oleoresin secreted onto the leaf surface and still harvested on Crete by brushing the shrubs. Herodotus described Arabs collecting it from the beards of grazing goats. It is a perfumery fixative and a different commercial product from the tea.

Common Names

• Rock rose, pink rock rose, hoary rock rose

• Cistus incanus, Cistus x incanus, Cistus creticus, Cistus villosus

• Cistus tea, Cistustee, czystek (Polish), kisthos or ladania (Greek)

• Labdanum or ladanum for the resin, which is not laudanum, the nineteenth century opium tincture

Primary Active Compounds

• Ellagitannins, chiefly punicalagin and punicalagin gallate, plus terflavin A and cistusin, a new ellagitannin isolated by Fecka and colleagues in 2020

• Flavonol glycosides, dominated by myricetin-3-O-rhamnoside (myricitrin), with quercetin-3-O-rhamnoside (quercitrin), rutin, hyperoside and isoquercetin

• Proanthocyanidin oligomers and polymers averaging 7 to 8 flavan-3-ol units, with a procyanidin to prodelphinidin ratio near 1:5 (Mansoor 2016)

• Flavan-3-ols including catechin, gallocatechin, epigallocatechin gallate and gallocatechin-3-gallate

• Labdane-type diterpenes in the resin and volatile oil: manoyl oxide, 13-epi-manoyl oxide, 3-acetoxy-manoyl oxide, 3-hydroxy-manoyl oxide, sclareol

• Carvacrol, a monoterpene phenol, in the volatile oil

Key Note

The Committee on Herbal Medicinal Products stated in its March 2025 assessment that no constituent with known therapeutic activity or active marker can be recognized for this plant. It settled for calling polyphenolic metabolites the analytical markers. United States supplement labels do not state a marker percentage, because there is no agreed marker to state.

Primary Functions & Benefits

Cistus is a polyphenol delivery vehicle with a short list of effects that have been measured in humans and a long list that have only been measured in glassware.

Upper respiratory symptom relief. The only endpoint with randomized placebo-controlled human data, and only for the CYSTUS052 lozenge. Symptom scores fell more on Cistus than on placebo over the course of treatment, and C-reactive protein fell significantly in the treatment arm (Kalus 2009, n=160).

Surface effects in the mouth. Wittpahl and colleagues (Planta Medica 2015;81:1727-1735) identified 29 polyphenols in four commercial Cistus teas and showed in situ that a rinse reduced initial bacterial colonization of enamel samples exposed to oral fluids for eight hours, and made the acquired enamel pellicle more electron dense under transmission electron microscopy. This is a contact effect on a surface, not a systemic one.

Gingival inflammation in combination. Di Minno and colleagues (Nutrients 2024;16:862) randomized 60 adults aged 18 to 70 to two chewing gums daily or placebo for three months, delivering 160 mg per day of a combined Scutellaria lateriflora and Cistus x incanus preparation. Gingival bleeding index, modified gingival index, pain and clinical global impression all improved against placebo, the bleeding index at p less than 0.001. Because the Cistus was never given alone, the trial cannot say what the Cistus contributed.

Lipids and oxidation markers. Kuchta and colleagues (Cardiology Journal 2021;28:534-542) gave 24 healthy adults 2 g of Cistus tea a day for 12 weeks. HDL cholesterol rose 4 percent from 47 to 50 mg/dL (p=0.033), triglycerides fell 14 percent from 71 to 60 mg/dL (p=0.013), malondialdehyde fell 16 percent (p less than 0.01) and advanced oxidation protein products fell 18 percent (p less than 0.001). Total and LDL cholesterol did not move. There was no control group and no randomization, so this is a before-and-after pilot and should be read as one.

Forms & Standardization

Loose herb for tea or decoction. The form the EU monograph covers. A decoction extracts roughly 9.5 percent polyphenols from the herb against roughly 2 percent for a simple infusion, according to unpublished data the HMPC reviewed. That is close to a fivefold difference between boiling the herb and pouring hot water over it, and retail packages generally do not explain it.

CYSTUS052. The ethanolic extract used in all three clinical studies. Extraction solvent 20 percent ethanol, polyphenol content greater than 26 percent. It is a proprietary preparation from a single selected variety and it is not what sits in a bag of loose Cistus tea.

Registered German lozenge. One traditional herbal medicinal product was registered in Germany in 2015: dry extract from Cisti incani herba at a drug-to-extract ratio of 4-9:1, extraction solvent water, in a compressed lozenge. Single dose 76.8 to 153.6 mg, daily dose 460.8 to 921.6 mg, indicated as a demulcent for oral or pharyngeal irritation in adults and adolescents over 12. The registered indication is soothing a sore throat.

Swiss medical device lozenge. On sale since November 2009, containing 73.5 mg of Cistus villosus extract, which is a synonym for C. creticus subsp. eriocephalus.

United States hydroalcoholic tinctures. Typically 1:5 in organic cane ethanol at 42 to 52 percent alcohol, dosed at 1 mL two or three times daily. The one used in the most-cited Borrelia work was a 45 percent ethanol extract of aerial parts. None of these carry a standardization percentage.

What is not standardized. Starzec and colleagues (Antioxidants 2023;12:553) analyzed 52 commercial C. incanus teas from Turkey, Albania, Greece and unspecified origins. Total polyphenols ranged from 5.5 to 23 percent of dry weight and ellagitannins from 2.5 to 19 percent. That is a greater than fourfold spread between the weakest and strongest product on the shelf, invisible from the outside of the bag. Turkish material carried more ellagitannin and higher FRAP and ABTS values than Albanian or Greek.

Which the human trials used. The two Kalus studies and the 2002 Kiesewetter observation used CYSTUS052. The Kuchta pilot used ordinary loose-leaf tea at 2 g a day. The Di Minno gum used a combination product. Nothing sold in the United States as a Lyme or biofilm supplement has been used in a controlled human trial of anything.

Food Sources

Cistus is not a food constituent. It is a beverage plant, and the beverage is the traditional form.

The tea. In the Kuchta pilot the first infusion of 2 g of herb in 250 mL of boiling water for three minutes yielded 98.5 plus or minus 1.3 mg gallic acid equivalents per gram of dry weight, with 10.9 mg caffeic acid equivalents per gram of phenolic acids and 2.5 mg quercetin equivalents per gram of flavonoids. Participants reinfused the same leaf three times, and the second and third infusions yielded 85.3 and 78.5 mg gallic acid equivalents per gram, so on 2 g of herb the three infusions together deliver roughly 525 mg of total polyphenols per day. A separate measurement put the total phenolic content of a water extract at 14.8 percent as gallic acid equivalents (Ziagova 2022).

Against ordinary tea. Jeszka-Skowron and colleagues compared Cistus with Camellia sinensis, rooibos and Hoan Ngoc tea in 2018. Cistus infusions contained 1.02 to 2.73 mg/g of catechins against 1.56 to 82.65 mg/g for Camellia, so green tea can carry thirty times more catechin. Cistus does contain catechin-3-gallate, which none of the Camellia infusions did. Trigonelline was higher in Cistus at 6.29 to 14.34 micrograms per gram, comparable to rooibos at 10.54 to 14.29. Caffeine, theobromine and theophylline were found practically only in Camellia at 6.22 to 14.19 mg/g, so Cistus tea is naturally caffeine free.

Traditional use. Cistus tea is still drunk on Crete against gastrointestinal complaints and cough with cold, and in Cyprus for bronchitis. In Turkey a 5 percent infusion of C. creticus and Cistus salviifolius leaves is used for digestive trouble and has a documented laxative reputation (Petereit 1991).

Labdanum as a separate product. The oleoresin goes to the fragrance industry, not the supplement aisle, and it is chemically a different thing. Rauwald and colleagues (Phytomedicine 2019;60:152977) found Cretan labdanum from C. creticus rich in manoyl oxides while Spanish labdanum declared as Cistus ladanifer contained mainly simple alkanes with at most traces of epi-manoyl oxide. The labdane diterpenes behind the anti-Borrelia and anti-dengue results live in the resin and the volatile oil, and the volatile oil is only about 0.10 percent of the leaf.

Who Should Take Cistus

People with a sore throat or an ordinary cold who want a cheap, low-risk demulcent. This is the registered indication in Germany and the one place a randomized placebo-controlled trial exists. Expect a symptom score that comes down a little faster, not a cure.

People who want a caffeine-free polyphenol-dense daily beverage. At roughly 525 mg of polyphenols from a 2 g daily portion brewed three times, Cistus tea is a reasonable substitute for a second cup of coffee, and the 12-week pilot in 24 healthy adults moved HDL, triglycerides and two oxidation markers in the expected direction.

People with gingivitis, as an adjunct. The enamel pellicle and gingivitis data are the most mechanistically coherent thing about this plant, because the polyphenols act where they physically touch. Swishing before swallowing costs nothing.

Who Should AVOID or Use Caution

Contraindications

• Known hypersensitivity to the active substance. This is the only contraindication in the EU monograph, which uses no family-level wording.

• Pregnancy and lactation. The HMPC states safety has not been established and recommends against use, because there is no reproductive or developmental toxicity data at all.

• Children and adolescents under 18. The monograph does not recommend use, despite children as young as 5 having been enrolled in the CYSTUS052 studies without separate reporting.

Use Caution

• People treating diagnosed Lyme disease. Substituting Cistus for doxycycline, amoxicillin or ceftriaxone in early Lyme is a decision with a documented consequence, and no trial supports it. If a patient chooses to drink Cistus tea, it goes alongside those antibiotics, never instead of them.

• People with iron deficiency or on iron therapy. Cistus is tannin-dense and tannins block nonheme iron absorption.

• People taking any medication with a narrow therapeutic index. The HMPC recorded no interaction data at all, which is an absence of study, not a finding of safety.

• Anyone buying loose herb of unstated species. Nine of 15 trade samples in one 2021 analysis chemically resembled white-flowered Cistus species rather than C. creticus.

Critical Safety Point

In vitro activity against Borrelia burgdorferi is not evidence of clinical benefit in Lyme disease. Cistus killed spirochetes in a 96-well plate. So did six of the other fourteen agents in the same screen. Untreated or undertreated early Lyme disease can progress to carditis, meningitis, facial palsy and arthritis. The plant has never been given to a single Lyme patient in a registered trial. A search of ClinicalTrials.gov on 26 September 2026 for "Cistus incanus" and for "Cistus creticus" returned zero studies in each case.

Recommended Dosages

Decoction, per the EU monograph. 10 g of comminuted herb in 200 mL of water, boiled until 100 mL remains, roughly 20 minutes, one to three times daily. Total daily dose 10 to 30 g of herb. Adults and the elderly only.

Herbal infusion, per the EU novel food authorization. 3 g of herb per day, about two cups. This is the legally stated intended daily intake for the authorized novel food designation "Cistus incanus L. Pandalis herb," and it is roughly a third to a tenth of the monograph decoction dose, which tells you how differently two EU regulators looked at the same plant.

Tea as used in the only human pilot study. 2 g of dried herb per day, brewed in 250 mL of boiling water for three minutes and reinfused three times, for 12 weeks (Kuchta 2021).

Registered lozenge. 76.8 to 153.6 mg of the 4-9:1 aqueous dry extract per lozenge, one or two lozenges every three hours, up to 460.8 to 921.6 mg a day.

Trial lozenge dose. Two lozenges six times a day, so 12 lozenges, in the 300 patient open trial against green tea (Kalus 2010). The lozenge count and duration used in the 160 patient placebo-controlled trial are not reported in the accessible record. The retail food supplement descended from that product is described on German pharmacy pages as six lozenges a day delivering an average of 123 mg of total polyphenols, half the open trial's lozenge count.

Tincture. 1 mL of a 1:5 extract two to three times daily is the common United States label instruction, equivalent to roughly 400 to 600 mg of dried herb a day. No trial has tested a tincture.

Duration

The monograph says to consult a clinician if symptoms persist beyond one week. The longest human exposure on record is 12 weeks in 24 people. There is no safety data past three months in humans at any dose.

Timing & Administration

Take the lozenge or the tea during acute symptoms rather than as a standing preventive, since the only positive respiratory trial was treatment of an established infection rather than prophylaxis.

For oral and throat effects, hold the liquid in the mouth. The Kiesewetter observation used gargling before swallowing, two minutes at a time, every three hours on day one and five times a day thereafter, while the in situ enamel work used rinses over enamel specimens.

Separate Cistus from iron supplements and from iron-rich meals by at least two hours. Polyphenol-rich beverages exert their strongest inhibition of nonheme iron absorption when consumed with the meal.

Brew hard, and brew the leaves rather than the sticks. The monograph decoction boils for 20 minutes, while the three-minute steep most packages recommend lands closer to the 2 percent polyphenol infusion than the 9.5 percent decoction. Riehle and colleagues (Journal of Agricultural and Food Chemistry 2014;62:10978-10988) separated four commercial teas into leaf and stem, quantified the wood fraction by cellulose content, and found the highest infusion phenolics came from leafy material at small particle size. Bags heavy with woody stem yield less of what you paid for.

Timeline of Effects

Days 1 to 7, upper respiratory symptoms. The Kalus placebo-controlled trial reported divergence in symptom score over the course of treatment, and the Kiesewetter observation used one week of gargling. If a cold is going to respond, it responds inside the length of the cold.

Immediately, oral surface effects. The enamel pellicle changed within a single exposure of over eight hours after rinsing.

Four to twelve weeks, gum health. The Di Minno trial measured monthly and reported significant improvement in gingival bleeding and the modified gingival index by month three.

Six to twelve weeks, lipids and oxidation markers. Kuchta sampled blood at baseline, 6 weeks and 12 weeks. Malondialdehyde and advanced oxidation protein products had already fallen their full amount by week 6, 20 to 15 and 66 to 53 micromolar, and then did not move again between week 6 and week 12, 15 to 15 and 53 to 54. Whatever the oxidation markers do, they do it in the first six weeks.

When to conclude it is not working. For a cold, seven days, which is the trial length and also the monograph's referral threshold. For gum health, three months. For anything else, there is no fair-trial length because there is no trial.

Benefits of Taking Cistus

• Measured symptom relief in the common cold, in 160 randomized patients, with a matching fall in C-reactive protein. Modest, real, specific to one extract.

• A drop in gingival bleeding over three months in 60 randomized adults, in combination with skullcap.

• Reduced initial bacterial adhesion to enamel over an exposure of more than eight hours after a rinse.

• Small favorable movements in HDL, triglycerides and two oxidation markers over 12 weeks in an uncontrolled pilot of 24 people.

• A high polyphenol load without caffeine. Roughly 525 mg from a 2 g daily portion brewed three times, no theobromine, no theophylline.

• Alpha-glucosidase inhibition in vitro, with whole extracts at IC50 125 to 145 micrograms/mL and isolated ellagitannins at IC50 0.7 to 1.1 micromolar, against acarbose at 3.3 millimolar in the same assay (Starzec 2023). No human glycemic trial exists.

• Broad in vitro antiviral activity. Cistus extract inhibited HIV-1 at EC50 8.06 micrograms/mL and EC90 15.5 micrograms/mL, with a polyphenol-enriched fraction reaching EC50 0.7 to 2.0 micrograms/mL and no resistant virus after 24 weeks of continuous passage (Rebensburg, Scientific Reports 2016;6:20394). None of this has been tested in a person with any viral infection other than an undifferentiated cold.

Potential Negatives & Side Effects

Reported adverse effects are few and mild, and the reporting base is small enough that this should be read as a lack of signal rather than a clean record.

• Astringency and dry mouth. The tea is heavily tannic. Punicalagin derivatives reached 161.2 mg/g in one trade sample.

• Gastrointestinal upset and loose stools. The laxative reputation of C. creticus infusion in Turkish practice is documented at 5 percent strength, and hydrolyzable tannins at high intake are a plausible cause.

• Contact allergy. English and Cronin reported a case in 1988 of a 53-year-old keen gardener with dermatitis of the wrists and ankles that recurred each summer. Patch testing with 40 garden plants could not establish causality, but sequential open application tests, rubbing each leaf on the forearm, produced a reaction to Cistus creticus alone.

• Hypersensitivity. Reviewing pharmacovigilance data to November 2022, the HMPC found three non-serious hypersensitivity reports in EudraVigilance following a 4-9:1 Cistus water extract, plus two in VigiBase, both in men in Morocco and both alongside another plant.

• Reduced iron absorption. See Interactions.

• No serious adverse events or deaths have been reported. The HMPC concluded from the Kalus studies only that the incidence of undesirable effects for Cistus is low.

Deficiency Symptoms

There is no such thing as a Cistus deficiency. The plant supplies no nutrient the body requires, has no recommended intake, no biomarker of status and no clinical sign of absence. Nobody has ever been diagnosed with a rock rose shortfall.

What cistus addresses

Symptoms, not deficits. A scratchy throat, a cold that is already in progress, bleeding gums, and in a single uncontrolled pilot, a lipid panel that moved a few percent. These are situations, not nutritional gaps, and each one resolves on its own timescale whether or not you drink the tea.

Bottom line

If you stop taking Cistus, nothing happens. That is the correct baseline expectation for any plant in this category, and the honest comparison for Cistus is not against a deficiency but against a cup of green tea, which costs less and carries up to thirty times the catechin.

Toxicity Symptoms

At high intake

No human overdose has been reported, and the HMPC recorded none. The animal data comes from unpublished studies submitted by interested parties on an aqueous extract containing at least 20 percent polyphenols. Single-dose oral toxicity in Sprague Dawley rats was run to a cut-off value of 5,000 mg/kg body weight (Bhide 2009). A 28-day repeat-dose gavage study at 0, 100, 500 and 1,000 mg/kg body weight with a 14-day recovery period found no statistically significant effects in either sex, giving a NOAEL of at least 1,000 mg/kg body weight (Bhide 2010). At high tannin intake the realistic problems are gastric irritation and impaired mineral absorption rather than systemic toxicity.

Signs to reduce or stop

• Persistent nausea, stomach pain or loose stools

• A rash, hives, lip or tongue swelling, or wheeze, all of which mean stop and do not rechallenge

• New or worsening fatigue, pallor or shortness of breath in anyone with borderline iron status who is drinking it with meals

• Any cough that lasts beyond a week, or arrives with breathlessness, fever or purulent sputum, which the monograph flags as a reason to see a clinician rather than to increase the dose

General note

Cistus was assessed as non-mutagenic in the bacterial reverse mutation assay across five Salmonella typhimurium strains, TA98, TA100, TA102, TA1535 and TA1537, with and without S9 (Wallner 2009), and in an in vitro mammalian cell gene mutation assay at the thymidine kinase locus in L5178Y mouse lymphoma cells (Kraft 2009). Carcinogenicity and reproductive toxicity have never been tested. The HMPC declined to extend those genotoxicity results to the tea, on the reasoning that a 20 percent polyphenol extract is a different composition from a 9.5 percent decoction, and it refused a European Union list entry on that basis.

How Cistus Works

The plausible mechanisms are physical rather than pharmacological, and they depend on where the polyphenols are and what they can stick to.

Surface binding and protein precipitation. Polymeric polyphenols bind proteins nonspecifically. Ehrhardt and colleagues (Antiviral Research 2007;76:38-47) showed that CYSTUS052 at 50 micrograms/mL reduced progeny influenza titers by up to two logs across avian and human subtypes, and attributed it to polymeric polyphenols coating the virion and blocking hemagglutinin from reaching cellular receptors. Because the mechanism is physical, virus did not develop resistance, while amantadine produced resistant variants within a few passages. The same logic explains the enamel pellicle work: the polyphenols change the protein layer bacteria try to attach to.

Virion targeting rather than cell targeting. Rebensburg and colleagues found the anti-HIV activity aimed at the virus particle, preventing attachment to the cell surface and preventing envelope proteins binding heparin. Cytotoxicity was low, with CC50 at or above 250 micrograms/mL for the whole extract and above 1,200 micrograms/mL for the polyphenol-enriched fraction.

Diterpene antimicrobial activity, in the resin only. Rauwald and colleagues isolated carvacrol and four manoyl oxides from Cretan labdanum and tested them individually against Borrelia burgdorferi sensu stricto. Epi-manoyl oxide was the strongest, matching amoxicillin in that assay. These compounds sit in the volatile oil and the resin, at about 0.10 percent of the leaf, and they are poorly water soluble.

Alpha-glucosidase inhibition. Ellagitannins inhibit the intestinal enzyme that releases glucose from disaccharides, at IC50 values three orders of magnitude below acarbose in the same experiment. This is a luminal effect on a brush-border enzyme, which is one of the few polyphenol mechanisms that does not require absorption.

What the mechanism does not explain. Human pharmacokinetic data for Cistus does not exist. The HMPC recorded "no data available" for both pharmacodynamics and pharmacokinetics in humans. Large polymeric proanthocyanidins of 7 to 8 flavan-3-ol units are not meaningfully absorbed intact. Whatever Cistus does, the evidence points at mouth, throat and gut lumen rather than bloodstream.

Synergistic Supplements

• Zinc acetate or gluconate lozenges for the same acute sore throat window. Both act locally in the oropharynx, both have their own randomized data, and neither interferes with the other.

• Scutellaria lateriflora, the only combination with a randomized human trial behind it, at 160 mg a day of the combined preparation for gingivitis over three months.

• Vitamin C with food, which partially offsets the iron absorption penalty that tannin-heavy beverages impose, if Cistus is being drunk daily.

• Xylitol or a plain saline rinse alongside Cistus for oral use, since the mechanism is surface occupancy and two surface agents do not compete.

What not to build a stack around: there is no human data on Cistus with any other botanical except skullcap, and the in vitro synergy screens against Borrelia have not been repeated in an animal, let alone a person.

Interactions & What NOT to Take

The honest starting point is that the HMPC found no documented drug interactions from clinical trials or case reports, and also found no interaction studies. Those are different statements.

Iron. This is the interaction with real human data behind it, though the data is on tannins generally rather than Cistus specifically. Hurrell, Reddy and Cook (British Journal of Nutrition 1999;81:289-295) measured nonheme iron absorption from a bread meal using erythrocyte incorporation of radio-iron. Beverages carrying 20 to 50 mg of total polyphenols per serving cut absorption by 50 to 70 percent, and beverages carrying 100 to 400 mg cut it by 60 to 90 percent. Black tea reached 79 to 94 percent inhibition, peppermint tea 84 percent, chamomile 47 percent. A 2 g daily portion of Cistus tea brewed three times delivers roughly 525 mg of polyphenols, which puts it at or above the top of the higher band. Nobody has run this experiment with Cistus, so treat it as a strong inference rather than a measurement.

Named drugs to separate or watch:

• Ferrous sulfate, ferrous fumarate, ferrous gluconate and iron polysaccharide complex. Separate by at least two hours.

• Levothyroxine. Absorption is reduced by chelating and adsorbing substances taken concurrently. Take levothyroxine on an empty stomach and keep tea away from it, as you would with coffee.

• Acarbose and miglitol. Both are alpha-glucosidase inhibitors, and Cistus ellagitannins inhibit the same enzyme in vitro. Additive effects have not been measured in people, but a patient on acarbose who adds a strong daily decoction is running an untested combination.

• Doxycycline, amoxicillin, cefuroxime axetil, ceftriaxone. No documented interaction. The risk here is substitution, not chemistry.

What not to take Cistus instead of: any antibiotic prescribed for a confirmed bacterial infection, any antiretroviral, and any antiviral. The HIV results are cell culture results, and the influenza results are cell culture plus one mouse model.

Quality, Testing & Adulteration

This is the section where Cistus is worst served by its own market, and the evidence is unusually specific.

Species substitution is documented and common. Lukas and colleagues (Plants 2021;10:615) analyzed 1,153 individual plants from 127 populations across seven Cistus species plus 15 commercial trade samples bought from pharmacies and health retailers. Twelve of the 15 were labeled C. incanus, one C. creticus, and two carried no species designation. Only six clustered chemically with C. creticus or C. albidus. The other nine matched the profiles of white-flowered species, chiefly Cistus monspeliensis and Cistus salviifolius, and the authors then found small white flower fragments in some of them, confirming the chemistry by eye. Their conclusion was that trade batches are almost certainly not correctly designated, or are at minimum admixtures.

The chemistry that distinguishes them. C. creticus runs a median of about 15 mg/g punicalagin derivatives, 11 mg/g myricetin glycosides and 3 mg/g quercetin glycosides. C. salviifolius runs a median near 149 mg/g punicalagin derivatives with only about 4 mg/g myricetin glycosides. So a substituted product can test as very high in total tannin while being the wrong plant. Across the 15 trade samples, punicalagin derivatives ranged from below the limit of detection to 161.2 mg/g. One sample labeled C. incanus from Greece had punicalagin derivatives below detection entirely.

Even the DNA testing hits a wall. The most-cited Borrelia screen used a Cistus incanus product whose supplier commissioned DNA species identification from NSF International. The result, printed in the paper's own methods table, is that DNA analysis reports Cistus incanus and Cistus albidus as genetically indistinguishable. At least one widely sold United States tea lists both species on the label.

Batch variability is enormous even when the species is right. Viapiana and colleagues (Industrial Crops and Products 2017;107:297-304) analyzed 15 commercial products, seven from Turkey, four from Albania, one from Cyprus and three of unknown origin, and found geographic origin to be the main differentiator, with the unknown-origin samples lowest in phenolics and antioxidant capacity. Drying method matters too: Matlok and colleagues (Molecules 2020;25:2596) compared six drying regimes and got the highest polyphenol yield, 2.8 g per 100 g dry matter, from convection pre-drying at 50 degrees Celsius followed by vacuum-microwave finishing at 240 W.

What a certificate of analysis should show. Species confirmed by chromatographic profile rather than DNA alone, since DNA cannot separate C. creticus from C. albidus. Punicalagin and punicalagin gallate quantified in mg/g, myricetin-3-O-rhamnoside quantified, leaf-to-stem ratio or a cellulose figure standing in for wood content, country and year of harvest, heavy metals and pesticide residues. Almost no retail Cistus product states any of this, and the HMPC's own position that no marker compound has been agreed gives sellers cover for stating nothing.

What a buyer can verify. Look at the material. C. creticus has pink to purple petals, so white flower fragments in the bag are a red flag, and anything dominated by woody stem should go back. Ask for the harvest country, the harvest year and a punicalagin figure. A supplier who cannot name the species with an authority and cannot produce a number is selling dried plant matter of unknown identity.

Special Considerations

Regulatory status is split several ways. In the EU, Cistus sits under the novel food regulation. One specific material, designated "Cistus incanus L. Pandalis herb," is authorized on the Union list established by Commission Implementing Regulation (EU) 2017/2470, restricted to herbal infusions, at an intended daily intake of 3 g of herb or two cups, with that designation required on the label. Great Britain retained the authorization on leaving the European Union. Belgium, under a Royal Decree of 1997 updated in 2017, permits C. creticus fruit, leaf and resin in food supplements with no restriction on age, pregnancy, posology or duration. Poland lists several Cistus products as notified foods. In the United States it is a dietary ingredient sold under DSHEA with the standard disclaimer and no premarket review.

The trademark history is worth knowing. On 31 January 2019 the Court of Justice of the European Union, in Case C-194/17, Pandalis v EUIPO, upheld partial revocation of the CYSTUS EU trade mark for lack of genuine use, confined to food supplements not for medical purposes in Class 30. The court held that swapping a y for an i does not create distinctiveness when consumers read the sign as descriptive of the plant. A brand name that regulators treat as a plant name is a poor proxy for a standardized preparation.

The taxonomy is genuinely unsettled, not just sloppily reported. Lukas and colleagues sequenced one nuclear region (ITS) and two chloroplast regions (trnL-trnF and rpl32-trnL) across C. creticus populations and found two major evolutionary lineages, an Eastern Mediterranean clade sharing a chlorotype with the geographically distant C. albidus, and a Western Mediterranean clade shaped by hybridization (Plants 2021;10:1619). A product labeled C. creticus from Spain and one from Crete are not necessarily the same chemistry.

The Lyme question deserves plain language. People with persistent symptoms after Lyme treatment have a real problem and very little offered to them. Cistus entered that market on two laboratory papers and a clinician's protocol. Feng and colleagues (Frontiers in Medicine 2020;7:6) screened 12 botanicals against B. burgdorferi strain B31 and found Cistus incanus active, with a minimum inhibitory concentration of 0.25 to 0.5 percent and 29 percent residual viable cells at 1 percent, against Cryptolepis sanguinolenta at 0.03 to 0.06 percent. Cistus was not close to the best performer, and the authors stated plainly that in vivo work is needed. Whether Borrelia forms biofilms inside human beings is an open question rather than a settled premise, and "biofilm buster" is a marketing phrase, not a measured property.

Research Status & Evidence Quality

Tier 1, randomized controlled human data: three studies, one condition, one product family.

• Kalus 2009, Antiviral Research 84:267-271. n=160, placebo-controlled, ages 7 to 81, 129 completers at 82.5 percent of the Cistus arm and 80.0 percent of placebo, figures that do not reconcile arithmetically in the assessment report that carries them.

• Di Minno 2024, Nutrients 16:862. n=60, double-blind, placebo-controlled, three months, ISRCTN registered, gingivitis endpoints, Cistus given only in combination.

• Kalus 2010, Phytotherapy Research 24:96-100. n=300, 277 completers, ages 5 to 85, randomized but open and non-blinded. The comparator is green tea, another polyphenol beverage, not placebo.

Tier 2, uncontrolled human studies: Kuchta 2021, n=24, 12 weeks, open, no control. Kiesewetter 2002, 53 patients with tonsillopharyngitis against 18 green tea controls. Wittpahl 2015, in situ enamel pellicle.

Tier 3, animal: Droebner 2007, Balb/c and C57Bl/6 mice aged 6 to 8 weeks given aerosolized CYSTUS052 in inhalation chambers for five days and protected against clinical disease from H7N7 influenza, plus repeat-dose rat toxicology at up to 1,000 mg/kg. Two further rat studies sit in the assessment report: Attaguile 1995 found a short-boiled aqueous extract at 0.25 to 0.50 g/kg gave significant dose-related protection across five gastric ulcer models, and Karadag 2020 found a methanol extract gel shortened bleeding time in a tail-tip amputation model. That is the whole in vivo record.

Tier 4, in vitro: large and growing. HIV-1 and HIV-2, Ebola and Marburg pseudotypes, influenza A of multiple subtypes, dengue, SARS-CoV-2, HSV-1, HCoV-229E, Staphylococcus aureus, Streptococcus mutans, Borrelia burgdorferi, alpha-glucosidase, tyrosinase, DPPH, FRAP and ABTS.

Research Limitations

• No human trial has ever tested Cistus for Lyme disease, chronic infection, biofilm, Epstein-Barr virus, or immune modulation. These are the four things it is principally sold for in the United States.

• Zero registered trials. ClinicalTrials.gov returned no studies for "Cistus incanus" or "Cistus creticus" on 26 September 2026, and a single study for "Cistus," NCT05612243, a functional yogurt trial in 21 healthy participants with unknown status.

• The regulator will not extrapolate from the trials to the tea. The HMPC's conclusion is that no conclusion on clinical pharmacology or efficacy of the monographed preparation can be drawn, because all three clinical studies used a special branded extract.

• No human pharmacokinetics. Nothing is known about absorption, distribution or metabolism of Cistus polyphenols in people.

• The trials that exist are small and short, and mostly industry-adjacent. The largest is 300 participants in an open study against an active comparator, and the toxicology package is unpublished data submitted by interested parties.

• One published result points the other way entirely. In the dengue work of Kuchta and colleagues (Journal of Ethnopharmacology 2020;257:112316), the labdanum diethyl ether fraction GS5 suppressed DENV-2 proliferation completely at 30 micrograms/mL with over 90 percent cell viability, while the water-soluble fraction enhanced viral proliferation. In one virus model, the water-soluble polyphenols made things worse.

Summary & Key Takeaways

Bottom Line

Cistus is a cheap, caffeine-free tea with one narrow piece of randomized human evidence behind it, for the common cold, using a proprietary 26 percent polyphenol ethanolic extract in lozenge form at a dose the published record does not state. Everything else sold on its name in the United States, Lyme support, biofilm disruption, chronic infection, rests on cell culture work, and in the case of the Borrelia data, on a steam-distilled volatile oil that makes up 0.10 percent of the leaf and does not end up in your cup. Buy it for a sore throat, for your gums, or as a polyphenol-rich substitute for coffee. Buy it for Lyme disease and you are buying something no person has ever been enrolled in a trial to test.

Key Safety Points

• Do not substitute Cistus for antibiotics in diagnosed Lyme disease or any confirmed bacterial infection.

• Not recommended in pregnancy or lactation, and not recommended under 18, per the EU monograph, because reproductive toxicity has never been studied.

• Separate from iron supplements and iron-rich meals by at least two hours. A 2 g daily portion brewed three times carries roughly 525 mg of polyphenols, above the 100 to 400 mg band that cut nonheme iron absorption by 60 to 90 percent in human isotope studies.

• Stop for rash, swelling, hives or wheeze. Five hypersensitivity reports and one 1988 contact dermatitis case exist.

• A cough that outlasts a week, or comes with fever, breathlessness or purulent sputum, is a reason to see a clinician.

• Carcinogenicity and reproductive toxicity have never been tested in any species.

Special Note

Buy this plant by its chemistry or not at all. In the most careful published analysis, nine of 15 commercial trade samples were chemically not the species on the label, matching white-flowered Cistus monspeliensis or Cistus salviifolius instead, some with white petal fragments still in the bag. Total polyphenols across 52 commercial teas ranged from 5.5 to 23 percent, punicalagin derivatives across 15 trade samples from undetectable to 161.2 mg/g, and DNA testing cannot separate Cistus creticus from Cistus albidus. A seller who will tell you the harvest country, the harvest year, the leaf-to-stem ratio and a punicalagin number is selling you a known quantity. A seller who will tell you it disrupts biofilms is selling you a sentence that no one has ever measured in a human being.